Gepotidacin (Blujepa) — A New Antibiotic for Uncomplicated UTI
The FDA has approved gepotidacin (Blujepa – GSK), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, for oral treatment of uncomplicated urinary tract infections (uUTI) in female patients ≥12 years old who weigh ≥40 kg. Gepotidacin is the first triazaacenaphthylene antibiotic to be approved in the US.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2026-01-05
- DOI
- https://doi.org/10.58347/tml.2026.1745a
- Primary Topic
- Urinary Tract Infections Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00